socalTECH

JANUARY 18, 2011

and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.

Twiistup 145

Twiistup Avalon San Diego Conference 145

Xconomy

AUGUST 17, 2016

It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

JULY 10, 2016

After completing his MBA in 1985, Bock joined a now-defunct venture firm in Costa Mesa, CA. He found he didn’t enjoy being a traditional VC gatekeeper who said “yes” or “no” to startup pitches, according to his wife, Diane. “He It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures.

San Diego 40

San Diego Startup Avalon Venture Capital 40

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

DECEMBER 7, 2018

Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.

Technology 98

Technology Develop Development San Diego 98

Xconomy

APRIL 30, 2018

After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.

Technology 78

Technology Venture Capital San Diego Avalon 78

Xconomy

MARCH 23, 2017

Xconomy is convening life sciences and technology founders, executives, investors, and entrepreneurs for an afternoon of fireside chats and solo talks at Human Impact of Innovation. What are the emerging opportunities for investors and executives on these topics, and what role will San Diego play in the advancement of these technologies?

San Diego 52

San Diego Entrepreneur Technology Avalon 52